Selected Grants
A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Brincidofovir in Subjects with Adenovirus Infection
Clinical TrialPrincipal Investigator · Awarded by SymBio Pharmaceuticals Limited · 2022 - 2025Multicentre Study of nomacopan in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy
Clinical TrialPrincipal Investigator · Awarded by Akari Therapeutics · 2023 - 2025Identifying Predictors of Poor Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors
ResearchPrincipal Investigator · Awarded by National Marrow Donor Program · 2023 - 2024Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
Clinical TrialPrincipal Investigator · Awarded by Allovir, Inc. · 2022 - 2024Busulfan exposure-finding for SCID
Clinical TrialPrincipal Investigator · Awarded by Children's Hospital Los Angeles · 2020 - 2024Identifying Predictors of Poor Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors
ResearchPrincipal Investigator · Awarded by National Marrow Donor Program · 2018 - 2023Marcus Foundation Phase II MSC ASD
ResearchPhysician · Awarded by The Marcus Foundation · 2019 - 2022A Prospective and Partially Retrospective Study to Characterize Safety and Efficacy of Allogeneic HSCT for the Treatment of Childhood Cerebral Adrenoleukodystrophy
Clinical TrialPrincipal Investigator · Awarded by Bluebird Bio · 2015 - 2021A Phase 2, Single-arm, Open-label, Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients with Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell (HSC) Transplantation (HSCT)
Clinical TrialPrincipal Investigator · Awarded by Magenta Therapeutics · 2018 - 2020A Prospective Observational Study for the Long-Term Follow-Up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001
ResearchPrincipal Investigator · Awarded by Chimerix, Inc. · 2016 - 2020Magenta MGTA-456 (IMD-001) Stem Cell Laboratory (STCL) MTA
ResearchPrincipal Investigator · Awarded by Magenta Therapeutics · 2018 - 2019Practice patterns and incidence of adenovirus infections in hematopoietic cell transplant in the US
ResearchPrincipal Investigator · Awarded by Chimerix, Inc. · 2018 - 2019Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir vs Standard of Care for Trtmt of Adenovirus Infections in High-risk Pediatric Allo HCT Recipients
Clinical TrialPrincipal Investigator · Awarded by Chimerix, Inc. · 2018 - 2019A Phase 3 Open Label Multicenter Study of the Safety & Efficacy of Brincidofovir CMX001 in the Treatment of Early versus Late Adenovirus Infection. Chimerix Study CMX001-304
Clinical TrialPrincipal Investigator · Awarded by Chimerix, Inc. · 2014 - 2017A Multicenter Non-Interventional Study to Obtain Retrospective Data for Subjects Previously Diagnosed with Adenovirus Infection to serve as Matched Historical Controls for Study CMX001-304
ResearchPrincipal Investigator · Awarded by Chimerix, Inc. · 2015 - 2016External Relationships
- Bluebird bio
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.